3-bromo-4-butoxybenzaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-bromo-4-butoxybenzaldehyde
• 化学式: C₁₁H₁₃BrO₂
• 分子量: 257.127
• InChiKey: BLXYHURWFRBYDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-bromo-4-butoxybenzaldehyde 在 ammonium acetate 、 potassium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 25.5h， 生成 ethyl 2-(4-butoxy-3-cyanophenyl)-1-methoxy-4-methyl-1H-imidazole-5-carboxylate
  参考文献：
  名称：

  Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors

  摘要：

  Xanthine oxidase is a key enzyme that catalyses hypoxanthine and xanthine to uric acid, whose overproduction leads to the gout-causing hyperuricemia. In this study, a series of 1-hydroxy/methoxy-4-methy1-2-phenyl-1H-imidazole-5-carboxylic acid derivatives (4a-4k and 6a-6k) was synthesized and evaluated for their inhibitory potency against xanthine oxidase. The 1-hydroxyl substituted derivatives 4a-4k showed excellent inhibitory potency with IC50 values ranging from 0.003 mu M to 1.2 mu M, with compounds 4d (IC50 = 0.003 mu M), 4e (IC50 = 0.003 FM), and 4f (IC50 = 0.006 mu M) manifesting the most potent xanthine oxidase inhibitory potency that were comparable with that of Febuxostat (IC50 = 0.01 410). Lineweaver-Burk plot analysis revealed that representative compound 4f acted as a mixed-type inhibitor for xanthine oxidase. The basis of significant inhibition of xanthine oxidase by 4f was rationalized by its molecular docking into the active site of xanthine dehydrogenase. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.08.056
• 作为产物：
  描述：

  正溴丁烷 、 3-溴-4-羟基苯甲醛 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 以90%的产率得到3-bromo-4-butoxybenzaldehyde
  参考文献：
  名称：

  Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors

  摘要：

  Xanthine oxidase is a key enzyme that catalyses hypoxanthine and xanthine to uric acid, whose overproduction leads to the gout-causing hyperuricemia. In this study, a series of 1-hydroxy/methoxy-4-methy1-2-phenyl-1H-imidazole-5-carboxylic acid derivatives (4a-4k and 6a-6k) was synthesized and evaluated for their inhibitory potency against xanthine oxidase. The 1-hydroxyl substituted derivatives 4a-4k showed excellent inhibitory potency with IC50 values ranging from 0.003 mu M to 1.2 mu M, with compounds 4d (IC50 = 0.003 mu M), 4e (IC50 = 0.003 FM), and 4f (IC50 = 0.006 mu M) manifesting the most potent xanthine oxidase inhibitory potency that were comparable with that of Febuxostat (IC50 = 0.01 410). Lineweaver-Burk plot analysis revealed that representative compound 4f acted as a mixed-type inhibitor for xanthine oxidase. The basis of significant inhibition of xanthine oxidase by 4f was rationalized by its molecular docking into the active site of xanthine dehydrogenase. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.08.056

文献信息

• [EN] PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS<br/>[FR] DÉRIVÉS DE PHÉNYLE-PRÉNYLE D'ORIGINE MARINE ET SYNTHÉTIQUE, DESTINÉS AU TRAITEMENT DE MALADIES OU TROUBLES COGNITIFS, NEURODÉGÉNÉRATIFS OU NEURONAUX
  申请人：NOSCIRA SA

  公开号：WO2009098287A1

  公开（公告）日：2009-08-13

  The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.

  本发明涉及一类具有式（I）的苯基-烯丙基衍生物，以及它们在治疗认知、神经退行性或神经疾病或障碍，如阿尔茨海默病或帕金森病中的用途。本发明还涉及包含相同化合物的药物组合物。此外，本发明针对式（I）的化合物用于医疗用途，特别是用于治疗和/或预防认知、神经退行性或神经疾病或障碍，并且用于制造用于治疗和/或预防认知、神经退行性或神经疾病或障碍的药物的化合物。
• Compound
  申请人：POTTER Barry Victor Lloyd

  公开号：US20090111862A1

  公开（公告）日：2009-04-30

  There is provided a compound of Formula I wherein each T is independently selected from H, hydrocarbyl, —F—R, and a bond with one of D, E, P or Q, or together with one of P and Q forms a ring; Z is a suitable atom the valency of which is m; D, E and F are each independently of each other an optional linker group, wherein when Z is nitrogen E is other than CH 2 and C═O; P, Q and R are independently of each other a ring system; and at least Q comprises a sulphamate group.

  提供了一种公式为I的化合物，其中每个T独立地选自H、烃基、—F—R和与D、E、P或Q中的一个之一形成键，或与P和Q中的一个形成环；Z是适当的原子，其价为m；D、E和F各自独立地是可选的连接基团，其中当Z是氮时，E除了CH2和C═O之外；P、Q和R各自独立地是环系统；并且至少Q包含一个磺酰胺基团。
• PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS
  申请人：Lopez Ogalla Javier

  公开号：US20110092591A1

  公开（公告）日：2011-04-21

  The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.

  本发明涉及一类公式（I）的苯基-异戊烯基衍生物家族，以及它们在治疗认知、神经退行性或神经性疾病或疾病方面的用途，例如阿尔茨海默病或帕金森病。本发明还涉及包含这些化合物的制药组合物。此外，本发明针对公式（I）的化合物用于医疗用途，特别是用于治疗和/或预防认知、神经退行性或神经性疾病或疾病的用途，以及将这些化合物用于制造治疗和/或预防认知、神经退行性或神经性疾病或疾病的药物。
• 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS
  申请人：Sterix Limited

  公开号：EP1446388B1

  公开（公告）日：2013-01-09
• HUMAN PLASMA KALLIKREIN INHIBITORS
  申请人：BIOCRYST PHARMACEUTICALS, INC.

  公开号：US20170073314A1

  公开（公告）日：2017-03-16

  Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.